The majority of U.S. stock indices ended lower on Nov. 12, as rising U.S. treasury yields posed a headwind to the equities’ ...
Hidradenitis suppurativa (HS) is a relatively common skin disease, affecting as many as one percent of people worldwide. But ...
MarketWatch on MSN1d
Schrödinger’s stock pops as it enters collaboration pact with Novartis worth up to $2.5 billionSchrödinger Inc.’s stock soared 14% Tuesday to put in on track for its biggest one-day gain in a year, after the company said ...
Midtown-based drug discovery company Schrodinger has entered a deal to advance multiple projects with pharmaceutical giant ...
Novartis is paying $150 million for a closer look at Schrödinger’s catalog of programs. The Big Pharma will work with Schrödinger to advance some of the computing-enabled R&D shop’s discovery programs ...
In a report released yesterday, Evan Seigerman from BMO Capital maintained a Buy rating on Schrodinger (SDGR – Research Report), with a ...
Schrödinger shares rise as they announce a research partnership and licensing agreement with Novartis AG. Schrödinger will ...
Novartis (NVS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Steve Scala from ...
The price trend for Novartis (NVS) has been bearish lately and the stock has lost 5.1% over the past two weeks. However, the ...
Novartis expects to increase its annual sales by least 5% per year in the coming years, CEO Vas Narasimhan said in an ...
Novartis AG's revenue and core EPS topped analysts' expectations in Q3. Click here to read more on the analysis of NVS stock ...
Novartis (NVS) stock slips despite better than expected Q3 results amid concerns over a cancer drug added with its $3B ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback